Novo Nordisk Slashes Insulin Prices by Over 70%
Novo Nordisk’s recent announcement to slash US list prices of two insulin products by more than 70% is undeniably a significant event. This dramatic price reduction, while seemingly a benevolent act, is a complex issue with multiple contributing factors beyond simple corporate altruism.
The timing of this price cut is intriguing, coinciding with the Biden administration’s negotiations with pharmaceutical companies to lower Medicare drug prices. While the full effects of these negotiations won’t be felt until 2026, Novo Nordisk’s proactive move suggests a response to the broader pressure for affordability in the insulin market. It’s tempting to see this as a direct result of political pressure, and perhaps it partially is, but it’s likely more nuanced than that.… Continue reading
Matt Underwood